Insider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells $42,485.04 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 40,851 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $1.04, for a total transaction of $42,485.04. Following the transaction, the insider owned 946,000 shares of the company’s stock, valued at approximately $983,840. This trade represents a 4.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Spero Therapeutics Stock Down 2.0%

NASDAQ:SPRO opened at $1.00 on Friday. Spero Therapeutics, Inc. has a 52 week low of $0.96 and a 52 week high of $3.08. The firm has a 50 day moving average of $1.14 and a 200 day moving average of $1.92. The stock has a market capitalization of $58.24 million, a price-to-earnings ratio of 9.27 and a beta of 1.59.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.29). Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. As a group, analysts expect that Spero Therapeutics, Inc. will post -0.97 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on SPRO shares. HC Wainwright boosted their target price on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Wall Street Zen cut Spero Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Zacks Research upgraded Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Weiss Ratings raised Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Finally, Cantor Fitzgerald initiated coverage on Spero Therapeutics in a research note on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Spero Therapeutics has an average rating of “Hold” and an average price target of $6.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SPRO. Alphabet Inc. acquired a new stake in shares of Spero Therapeutics during the second quarter worth $1,967,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics during the second quarter valued at $1,314,000. GSA Capital Partners LLP purchased a new stake in shares of Spero Therapeutics during the second quarter valued at $632,000. Global Retirement Partners LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $55,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.